It is now appreciated in the ovarian cancer literature that upon treatment with standard platinum-based chemotherapy, BRCA1- and BRCA2-associated malignancies have an improved prognosis compared to sporadic epithelial ovarian cancers [44]. This evidence concerns the gene BRCA1 and ovarian cancer.